Adjunctive brivaracetam for refractory partial-onset seizures: A randomized, controlled trial

Neurology

Volumn 75, Issue 6, 2010, Pages 519-525

  French, J A ^a   Costantini, C ^b   Brodsky, A ^b   Von Rosenstiel, P ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BRIVARACETAM; CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PLACEBO; SODIUM CHANNEL; TOPIRAMATE; VALPROIC ACID; 2 PYRROLIDONE DERIVATIVE; 2-(2-OXO-4-PROPYLPYRROLIDIN-1-YL)BUTANAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FATIGUE; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; INFLUENZA; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY PARTIAL ONSET SEIZURE; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; COMPARATIVE STUDY; DOSE RESPONSE; EPILEPSIES, PARTIAL; FOLLOW UP; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; SEIZURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLIDINONES; SEIZURES; YOUNG ADULT;

EID: 77955452826     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181ec7f7f     Document Type: Article

References (14)

1. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007;62: 382-389.
2. Kenda BM, Matagne AC, Talaga PE, et al. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 2004;47: 530-549.
3. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101: 9861-9866.
4. Zona C, Pieri M, Carunchio I, Curcio L, Klitgaard H, Margineanu D-G. Brivaracetam (ucb 34714) inhibits Na current in rat cortical neurons in culture. Epilepsy Res 2010;88:46-54.
5. Matagne A, Margineanu D-G, Kenda B, Michel P, Klit-gaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A Br. J Pharmacol 2008;154: 1662-1671.
6. Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males Br J Clin Pharmacol 2008;66:71-75.
7. Sargentini-Maier ML, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males Br. J Clin Pharmacol 2007;63:680-688.
8. Sargentini-Maier ML, Espie P, Coquette A, Stockis A. Pharmacokinetics and metabolism of C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dis-pos 2008;36:36-45.
9. von Rosenstiel P, Perucca E. Brivaracetam. In: Shorvon SD, Perucca E, Engel E Jr, eds. The Treatment of Epilepsy, 3rd ed. Chichester: Wiley-Blackwell; 2009:447-457.
10. Kasteleijn-Nolst Trenite DG, Genton P, Parain D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 2007;69:1027-1034.
11. International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes: Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989;30:389-399.
12. Leppik I, De RK, Edrich P, Perucca E. Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience. Epileptic Disord 2006;8:118-130.
13. Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 2007;48:1303-1307.
14. van Paesschen W, Brodsky A, von Rosenstiel P. Efficacy and tolerability of 50 and 150 mg/day brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial onset epilepsy. Epilepsia 2007; 48(suppl 6):329. Abstract.